Adicet Bio Appoints Nick Harvey as Chief Financial Officer
September 16 2020 - 7:00AM
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced the appointment of
Nick Harvey as Chief Financial Officer. Mr. Harvey will be
responsible for leading the company’s financial strategy and
management of activities related to accounting, capital markets and
business operations.
“We are delighted to welcome Nick to Adicet’s executive
leadership team,” said Chen Schor, President and Chief Executive
Officer of Adicet. “With his deep business and financial expertise,
Nick has demonstrated the ability to successfully guide teams
through significant organizational growth throughout his career.
His financial, strategic and business insights will undoubtedly add
great value to our team, and will be instrumental in our next phase
of growth.”
“I am pleased to join Adicet during this pivotal time in the
company’s strategic development,” said Nick Harvey, Chief Financial
Officer of Adicet Bio, Inc. “Adicet is uniquely positioned to
capitalize on the opportunities ahead and I look forward to
advancing its financial and business strategy to support its
long-term success as we advance our gamma delta T cell platform and
programs into the clinic.”
Mr. Harvey has over 20 years of experience in financial
operations, capital markets, investor relations and M&A
transactions as well as managing corporate growth for life science
companies. Mr. Harvey joins Adicet most recently from Centrexion
Therapeutics, a privately held biotechnology company, where he
served as Executive Vice President and Chief Financial Officer.
Previously, he served as the Chief Financial Officer of Radius
Health where he helped successfully complete its initial public
offering and transition from a research and development stage
company to a commercial organization. During his tenure at Radius,
he oversaw financial operations, business development, legal,
facilities, and information technology. Prior to that, Mr. Harvey
served as a Managing Director at Shiprock Capital, a venture
capital firm, where he managed investments and development of early
and late-stage companies. Mr. Harvey received his MBA from Harvard
Business School, and earned both a law degree and an undergraduate
degree in Economics from the Australian National University.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of “off-the-shelf”
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like antibodies to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in
patients. For more information, please visit our website
at http://www.adicetbio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
potential for the results of ongoing preclinical or clinical trials
and the efficacy of Adicet’s drug candidates. The use of words such
as, but not limited to, “believe,” “expect,” “estimate,” “project,”
“intend,” “future,” “potential,” “continue,” “may,” “might,”
“plan,” “will,” “should,” “seek,” “anticipate,” or “could” and
other similar words or expressions are intended to identify
forward-looking statements. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based on Adicet’s current beliefs, expectations and
assumptions regarding the future of Adicet’s business, future plans
and strategies, clinical results and other future conditions. New
risks and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. No representations
or warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Such forward-looking statements are subject to a number of
material risks and uncertainties including but not limited to:
(i) the outcome of any legal proceedings that may be
instituted against the parties and others related to the merger
agreement; (ii) unanticipated difficulties or expenditures relating
to the merger, the response of business partners and competitors to
the announcement or completion of the merger, and/or potential
difficulties in employee retention as a result of the announcement
or completion of the merger; (iii) the combined company’s
listing on the Nasdaq Global Market; (iv) the adequacy of the
combined company’s capital to support its future operations and its
ability to successfully initiate and complete clinical trials;
(v) the nature, strategy and focus of the combined company;
(vi) the difficulty in predicting the time and cost of
development of Adicet’s product candidates; (vii) Adicet’s
plans to develop and commercialize its product candidates,
including, but not limited to, ADI-001 and ADI-002; (viii) the
timing of initiation of Adicet’s planned clinical trials;
(ix) the timing of the availability of data from Adicet’s
clinical trials; (x) the timing of any planned investigational
new drug application or new drug application; (xi) Adicet’s
plans to research, develop and commercialize its current and future
product candidates; (xii) Adicet’s ability to enter into new
collaborations, and to fulfill its obligations under any such
collaboration agreements; (xiii) the clinical utility,
potential benefits and market acceptance of Adicet’s product
candidates; (xiv) Adicet’s commercialization, marketing and
manufacturing capabilities and strategy; (xv) Adicet’s ability
to identify additional products or product candidates with
significant commercial potential and to expand its pipeline in
oncology and other diseases; (xvi) developments and
projections relating to Adicet’s competitors and its industry;
(xvii) the impact of government laws and regulations;
(xviii) the impact of public health epidemics affecting
countries or regions in which we have operations or do business,
such as COVID-19, which has been labeled a pandemic by the World
Health Organization, the timing and anticipated results of Adicet’s
clinical trials; (xix) the risk that the results of Adicet’s
clinical trials may not be predictive of future results in
connection with future clinical trials; (xx) the timing and
outcome of Adicet’s planned interactions with regulatory
authorities; (xxi) Adicet’s ability to protect its
intellectual property position; (xxii) Adicet’s estimates
regarding future revenue, expenses, capital requirements and need
for additional financing; and (xxiii) those risks detailed in
Adicet’s definitive proxy statement/prospectus/information
statement filed with the SEC on August 21, 2020, as well as
discussions of potential risks, uncertainties, and other important
factors in Adicet’s subsequent filings with the Securities and
Exchange Commission. Any forward-looking statement speaks only as
of the date on which it was made. None of Adicet, nor its
affiliates, advisors or representatives, undertake any obligation
to publicly update or revise any forward- looking statement,
whether as result of new information, future events or otherwise,
except as required by law.
Adicet Bio., Inc.Investor and Media
ContactsAnne Bowdidgeabowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Apr 2024 to May 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From May 2023 to May 2024